References
- Arentz-HansenHGranumLGulsethHCTNF Inhibitors for Rheumatic Diseases Oslo, Norwegian Knowledge Centre for the Health Services, report 122006
- Arentz-HansenHPalmØNorderhaugINTNF Inhibitors for Rheumatic Diseases (Part 2). Effect and Side Effects Oslo, Norwegian Knowledge Centre for the Health Services, report 22007
- MoenENeilsonARAaserudMTNF Inhibitors for Rheumatic Diseases (Part 3). Health Economics Oslo, Norwegian Knowledge Centre for the Health Services, report 162007
- SæterdalIMørkNJDalakerMTNF Inhibitors and Efalizumab for the Treatment of Skin Diseases Oslo, Norwegian Knowledge Centre for the Health Services, report 152007
- RingerikeTElvsaasIKØCollPTNFα-inhibitors in Inflammatory Bowel Disease Oslo, Norwegian Knowledge Centre for the Health Services, report 322008
- BrennanABansbackNNixonRModelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegistryRheumatology2007461345135417562686
- ChenYFJobanputraPBartonPA systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectivenessHealth Technol Assess200610421229
- DoanQVChiouCFDuboisRWReview of eight pharmaeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the mangament of rheumatoid arthritisJ Manag Care Pharm20061255556916981801
- WuEChenLBirnbaumHCost of care for patients with rheumatoid arthirits receiving TNF-antagonist therapy using claims dataCurr Med Res Opin2007231749175917588306
- McLeodCBagustABolandAAdalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluationHealth Technol Assess200711281158
- Bravo VergelYHawkinsNSThe cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritisRheumatology2007461729173517956918
- ArseneauKOCohnSMCominelliFCost utility of initial medical management for Crohn’s disease perioanal fistulaGastroenterology20011201640165611375946
- ClarkWRafteryJSongFSystematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s diseaseHealth Technol Assess2003716712709295
- Jaisson-HotIFlourieBDescosLManagement for severe Crohn’s disease: a lifetime cost-utility analysisInt J Technol Assess Health Care20042027427915446756
- MarshallJBlackhouseGGoereeRInfliximab Management for the Treatment of Crohn’s Disease: a Systematic Review and Cost-utility AnalysisOttawaCanadian Coordinating Office for Health Technology Assessment (CCOHTA) Technology report No. 242002
- JönssonBKobeltGSmolenJThe burden of rheumatoid arthritis and access to treatment uptake of new therapiesEur J Health Econ200886186
- KavanaughAEconomic consequences of established rheumatoid arthritis and its treatmentBest Pract Res Clin Rheum200721929942
- KoldingsnesWNossentHCEpidemiology of ANCA associated vasulitisNor Epidem2008183748
- WattsRALaneSEScottDGEpidemiology of vasculitis in EuropeAnn Rheum Dis2001601156115711760724
- BaklandGNossentHCGranJTIncidence and prevalence of ankylosing spondylitis in northern NorwayArthritis Rheum20055385085516342091
- HeibergMSKoldingsnesWMikkelsenKThe comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter studyArthritis Rheum20085923424018240258
- ShivanandaSLennard-JonesJLoganRIncidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)Gut1996396906979014768
- Juillard-CondatBCopnstantinACambon-ThompsonAImpact of etanercept on the costs of theumatoid arthritis (RA): results from a French observational studyJoint Bone Spine200875252817913554
- WelsingPMJSeverensJLHartmanMModeling the 5-year cost effectiveness of treatment strategies including tumour necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the NetherlandsArthritis Rheum20045196497315593319
- LieSAVollsetSEFurnesOThe Norwegian Arthroplasty Register: beneficial for patients and for the Norwegian health care systemNor J Epidem2004145763
- SørensenJAndersenLSThe case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysisPharm Econ200523289298